MIF and hyperlipidemia: We previously found that administering olanzapine (OLZ), a common AAP, as monotherapy over two months led to increased circulating MIF levels in first-episode SZ patients, and this rise was positively associated with elevated body weight gain, insulin resistance, and hyperlipidemia [17].